Engineered organ developer Harvard Apparatus Regenerative Technology has done all it can to disassociate itself from the surgeon Paolo Macchiarini. The Holliston, MA-based company is now known as Biostage (NASDAQ: BSTG), uses a different technology, is led by a different management team, and no longer helps Macchiarini perform the surgeries that led to the company’s founding in the first place.
That’s a good thing, because the controversy for Macchiarini, who had been a world-renowned surgeon and stem cell scientist, continues to grow.
